Publications powered by Harvard Catalyst Profiles

  1. Epigenetic transcriptional reprogramming by WT1 mediates a repair response during podocyte injury. Sci Adv. 2020 Jul; 6(30):eabb5460. View abstract
  2. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. J Cell Mol Med. 2017 07; 21(7):1300-1314. View abstract
  3. A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment. Oncotarget. 2016 Nov 15; 7(46):74931-74946. View abstract
  4. Current insights into the sulfatase pathway in human testis and cultured Sertoli cells. Histochem Cell Biol. 2016 Dec; 146(6):737-748. View abstract
  5. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia. Circulation. 2016 Jul 05; 134(1):61-72. View abstract
  6. WT1 targets Gas1 to maintain nephron progenitor cells by modulating FGF signals. Development. 2015 Apr 01; 142(7):1254-66. View abstract
  7. Reference gene validation for RT-qPCR, a note on different available software packages. PLoS One. 2015; 10(3):e0122515. View abstract
  8. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014 Jul; 25(7):1415-29. View abstract
  9. Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2). J Biol Chem. 2013 Jun 21; 288(25):18407-20. View abstract
  10. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011 Dec 13; 20(6):768-80. View abstract
  11. WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier. J Am Soc Nephrol. 2011 Jul; 22(7):1286-96. View abstract
  12. Copy number variation in patients with disorders of sex development due to 46,XY gonadal dysgenesis. PLoS One. 2011 Mar 07; 6(3):e17793. View abstract
  13. Expression regulation and function of heparan sulfate 6-O-endosulfatases in the spermatogonial stem cell niche. Glycobiology. 2011 Feb; 21(2):152-61. View abstract
  14. Characteristics of testicular dysgenesis syndrome and decreased expression of SRY and SOX9 in Frasier syndrome. Mol Reprod Dev. 2008 Sep; 75(9):1484-94. View abstract
  15. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer. 2008 Sep 01; 113(5):1080-9. View abstract
  16. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol. 2007 Mar; 18(3):719-29. View abstract
  17. Recessive missense mutations in LAMB2 expand the clinical spectrum of LAMB2-associated disorders. Kidney Int. 2006 Sep; 70(6):1008-12. View abstract
  18. STK11 status and intussusception risk in Peutz-Jeghers syndrome. J Med Genet. 2006 Aug; 43(8):e41. View abstract
  19. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006 May 15; 12(10):3209-15. View abstract
  20. A novel WT1 missense mutation presenting with Denys-Drash syndrome and cortical atrophy. Nephrol Dial Transplant. 2006 Feb; 21(2):518-21. View abstract
  21. STK11 genotyping and cancer risk in Peutz-Jeghers syndrome. J Med Genet. 2005 May; 42(5):428-35. View abstract
  22. Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene. J Pediatr Hematol Oncol. 2004 Dec; 26(12):820-3. View abstract
  23. Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet. 2004 Nov 01; 13(21):2625-32. View abstract
  24. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. . 2004 Jun 15; 127A(3):249-57. View abstract
  25. Slow progressive FSGS associated with an F392L WT1 mutation. Pediatr Nephrol. 2004 Mar; 19(3):353-6. View abstract
  26. BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol. 2004 Jan; 24(2):537-49. View abstract
  27. Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res. 2003 Jun; 9(6):2005-14. View abstract
  28. Germline Wilms tumor suppressor gene (WT1) mutation leading to isolated genital malformation without Wilms tumor or nephropathy. J Pediatr. 2001 Mar; 138(3):421-4. View abstract
  29. Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1. Genes Dev. 2001 Feb 01; 15(3):328-39. View abstract
  30. Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. Br J Cancer. 2000 Jul; 83(2):177-83. View abstract
  31. Extraintestinal polyps in Peutz-Jeghers syndrome: presentation of four cases and review of the literature. Deutsche Peutz-Jeghers-Studiengruppe. Int J Colorectal Dis. 2000 Apr; 15(2):118-23. View abstract
  32. Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene. Pediatr Res. 1999 Feb; 45(2):187-90. View abstract
  33. Genomic structure, alternative transcripts and chromosome location of the human LIM domain binding protein 1 gene LDB1. Cytogenet Cell Genet. 1999; 87(1-2):119-24. View abstract
  34. A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene. Hum Genet. 1998 Aug; 103(2):154-61. View abstract
  35. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations. Kidney Int. 1998 Jun; 53(6):1594-600. View abstract
  36. Ten novel mutations found in Aniridia. Hum Mutat. 1998; 12(5):304-13. View abstract
  37. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A. 1997 Apr 15; 94(8):3972-7. View abstract